Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2024 Earnings Call Transcript
Operator: Good day and welcome to the Adaptimmune Second Quarter 2024 Conference Call. All participants will be in a listen-only mode.
Adaptimmune Therapeutics Plc (ADAP)
Market is closed
News
- 1 - 10
- Next >>
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Adaptimmune Q1 2024 Financial and Business Update Conference Call. I would now like to turn the meeting over to Ms. Juli Miller.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript
Juli Miller: Good morning, thank you for joining us.
15 Top Performing European Stocks So Far in 2024
In this piece, we will take a look at the 15 top performing European stocks so far in 2024.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Adaptimmune’s Q3 Financial and Business Update Conference Call. I would now like to turn the meeting over to Ms. Juli Miller.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen and welcome to Adaptimmune’s Q2 Financial and Business Update Conference Call. I would now like to turn the meeting call over to Ms. Juli Miller.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2023 Earnings Call Transcript
Juli Miller: Good morning, and welcome to Adaptimmune's conference call to discuss our first quarter 2023 financial results and business updates.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2022 Earnings Call Transcript
Operator: Welcome to Adaptimmune and TCR2 joint webcast to discuss their strategic combination announced earlier this morning.
5 High Growth UK Stocks to Buy
Adaptimmune Therapeutics plc (NASDAQ:ADAP) is a biotechnology firm that develops tumor and cancer treatments. Some cancers that the firm is taking aim at include those of the lungs, head, and neck.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2022 Earnings Call Transcript
Juli Miller: Good morning and welcome to Adaptimmune's conference call to discuss our third quarter 2022 financial results and business update.
- 1 - 10
- Next >>
Billionaire Hedge Funds
